Company profile: Palleon Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of glycoimmune checkpoint inhibitors to treat cancer, including E-602, a bi-sialidase fusion protein in Phase 1/2 trials that degrades immunosuppressive sialoglycans to restore antitumor immunity; the EAGLE platform of engineered human sialidases to strip sialic acid from cancer and immune cells; HYDRA immunohistochemistry technology to quantify sialoglycan density; and autoimmune disease R&D programs.
Products and services
- EAGLE Platform: Enzyme-engineered platform that architects therapeutics with engineered human sialidase enzymes to remove sialic acid from cancer and immune cells, enabling comprehensive antitumor immune responses
- E-602: Clinical-stage bi-sialidase fusion protein that enzymatically degrades immunosuppressive sialoglycans on hypersialylated tumors and immune cells to restore antitumor immunity, currently in Phase 1/2 trials
- HYDRA Platform: Research-grade immunohistochemistry-based technology that quantifies immunosuppressive sialoglycan density in cancer patient samples to prioritize clinical development and evaluate pharmacodynamic activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Palleon Pharmaceuticals
Inviragen
HQ: United States
Website
- Description: Provider of life-saving vaccines in development to protect against emerging infectious diseases worldwide, including a lead dengue fever vaccine and a West Nile virus vaccine for North America.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inviragen company profile →
Dara Biosciences
HQ: United States
Website
- Description: Provider of oncology treatment and supportive care products, dedicated to commercialization as a specialty pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dara Biosciences company profile →
Exacis
HQ: United States
Website
- Description: Provider of development-stage immuno-oncology solutions, using mRNA-based cell reprogramming to create iPSC and mRNA-based gene editing to engineer iPSC, creating engineered NK and T cells designed to resist host immune rejection to harness the human immune system against cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exacis company profile →
NeoImmuneTech
HQ: South Korea
Website
- Description: Provider of T cell-centered novel immunotherapeutics, developing NT-I7, a drug candidate designed to amplify T cells to enhance immune responses in oncology and immunology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoImmuneTech company profile →
ADC Therapeutics
HQ: Switzerland
Website
- Description: Provider of targeted oncology therapies, developing antibody-drug conjugates and non-ADC products for hematological cancers and solid tumors using proprietary PBD-dimer technology. Offerings include ZYNLONTA (CD19 ADC), the LOTIS clinical trial program, ADCT-602 (CD22 ADC for acute lymphoblastic leukemia), Mipasetamab uzoptirine/ADCT-601 (AXL-targeting), PBD-dimer technology, and support for investigator-initiated trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Palleon Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Palleon Pharmaceuticals
2.2 - Growth funds investing in similar companies to Palleon Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Palleon Pharmaceuticals
4.2 - Public trading comparable groups for Palleon Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →